Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 124.44B +96.0% |
| Revenue (ttm) | 51.58B +4.1% |
| Net Income | 2.10B |
| EPS | 1.79 |
| Shares Out | n/a |
| PE Ratio | 59.17 |
| Forward PE | 12.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,687,134 |
| Open | 10,560 |
| Previous Close | 10,560 |
| Day's Range | 10,550 - 10,840 |
| 52-Week Range | 5,305 - 11,350 |
| Beta | 0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva Pharmaceutical Industries Q2 Earnings Call Highlights
Teva Pharmaceutical Industries NYSE: TEVA reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were lar...
TEVA Looks 71.0% Overvalued on GF Value⢠as Insider Selling Persists
TEVA Looks 71.0% Overvalued on GF Value⢠as Insider Selling Persists
Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 9.6% Rally? GF Value Says Overvalued
Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 9.6% Rally? GF Value Says Overvalued
Teva CEO on Q2 earnings: 'Good growth across the whole portfolio'
Richard Francis, President and CEO of Teva Pharmaceuticals, joins 'Squawk on the Street' to discuss Q2 results, drug pipeline, generics business, and more.
Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views
Teva's bullish guidance overshadowed mixed second-quarter results.
Watch CNBC's full interview with Teva Pharmaceuticals CEO Richard Francis
Richard Francis, President and CEO of Teva Pharmaceuticals, joins 'Squawk on the Street' to discuss Q2 results, drug pipeline, generics business and more.
Teva Pharmaceutical Industries Q2 2026 Disappoints: EPS 93.8% Below Estimates
Significant Miss. Teva Pharmaceutical Industries Limited (NYSE:TEVA) stumbled badly in Q2 2026, reporting non-GAAP diluted earnings of $0.02 per share again... The post Teva Pharmaceutical Industries ...
TEVA Looks 56.0% Overvalued on GF Value⢠as Insider Selling Persists
TEVA Looks 56.0% Overvalued on GF Value⢠as Insider Selling Persists
Is Teva Pharmaceutical Industries Ltd (TEVA) Facing Challenges After Q2 Earnings Miss? GAAP ...
Is Teva Pharmaceutical Industries Ltd (TEVA) Facing Challenges After Q2 Earnings Miss? GAAP Loss Per Share at $0.49, GF Score: 54/100
Teva Pharmaceutical Industries Earnings Call Transcript: Q2 2026
Q2 2026 saw robust growth in innovative products, offsetting generics declines, with raised guidance for AUSTEDO, AJOVY, and UZEDY. Free cash flow surged 31%, and the Emalex acquisition and biosimilars expansion support long-term growth.
Teva Pharmaceutical Industries Slides: Q2 2026
Teva Pharmaceutical Industries has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Teva Pharmaceutical Industries Earnings release: Q2 2026
Teva Pharmaceutical Industries released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Teva Pharmaceutical Industries Quarterly report: Q2 2026
Teva Pharmaceutical Industries has published its Q2 2026 quarterly earnings report on July 29, 2026.
Teva Pharmaceutical Industries Releases Q2 2026 Financial Results
Teva Pharmaceutical Industries Limited reported a sharp earnings miss for the second quarter of 2026, posting non-GAAP diluted earnings of $0. The post Teva Pharmaceutical Industries Releases Q2 2026 ...
UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in ...
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a recor...
Teva reports Q2 EPS 2c, consensus 11c
Reports Q2 revenue $4.14B, consensus $4.03B. Richard Francis, Teva‘s (TEVA) President and CEO, said: “Our second quarter reflects continued execution of our Pivot to Growth strategy. During the quarte...
Teva Pharmaceutical Industries Q2 26 Earnings Conference Call At 8:00 AM ET
(RTTNews) - Teva Pharmaceutical Industries (TEVA) will host a conference call at 8:00 AM ET on July 29, 2026, to discuss Q2 26 earnings results.
‘It is okay not to be okay’: NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness
The hall-of-famer has partnered with Teva to raise awareness on Tardive Dyskinesia, a chronic movement disorder. He’s in good company with Serena & co.
TEVA Looks 55.9% Overvalued on GF Value⢠as Earnings Outlook Dims
TEVA Looks 55.9% Overvalued on GF Value⢠as Earnings Outlook Dims
TEVA Maintained by Piper Sandler -- Price Target Raised to $44.00
TEVA Maintained by Piper Sandler -- Price Target Raised to $44.00
Stay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Teva Pharmaceutical Industries (TEVA), review projections for some of its key metrics to gain a deeper understanding of how the company might ha...
Teva price target raised to $44 from $42 at Piper Sandler
Piper Sandler analyst David Amsellem raised the firm’s price target on Teva (TEVA) to $44 from $42 and keeps an Overweight rating on the shares. The firm cites the inclusion…
Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%.
Teva's pivot toward branded drugs is benefiting the company's underlying performance and its stock price. While shares have pulled back recently, another big catalyst could play out in the years ahead...
Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right.
Teva's business is shifting away from generic drugs toward branded drugs. Operating margins could soar through next year, boosting earnings potential.